An instrument dedicated for modelling of pulmonary radiotherapy

Anne G. H. Niezink*, Nienke J. Dollekamp, Harriet J. Elzinga, Denise Borger, Eduard J. H. Boer, Jan F. Ubbels, Marleen Woltman- van Iersel, Annija H. D. van der Leest, Max Beijert, Harry J. M. Groen, Jan Kraan, Thijo J. N. Hiltermann, Anthonie J. Wekken, van der, John W. G. van Putten, Steven R. Rutgers, Remge M. Pieterman, Sander M. de Hosson, Anke W. J. Roenhorst, Johannes A. Langendijk, Joachim Widder

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

3 Citaten (Scopus)


Background and purpose: Radiotherapy plays a pivotal role in lung cancer treatment. Selection of patients for new (radio)therapeutic options aiming at improving outcomes requires reliable and validated prediction models. We present the implementation of a prospective platform for evaluation and development of lung radiotherapy (proPED-LUNG) as an instrument enabling multidimensional predictive modelling.

Materials and methods: ProPED-LUNG was designed to comprise relevant baseline and follow up data of patients receiving pulmonary radiotherapy with curative intent. Patient characteristics, diagnostic and staging information, treatment parameters including full dose-volume-histograms, tumour control, survival, and toxicity are scored. Besides physician-rated data, a range of patient-rated data regarding symptoms and health-related quality-of-life are collected.

Results: After 18 months of accrual, 315 patients have been included (accrual rate, 18 per month). Of the first hundred patients included, 70 received conformal (chemo)radiotherapy and 30 underwent stereotactic radiotherapy. Compliance at 3 and 6 months follow-up was 96-100% for patient-rated, and 8194% for physician-rated assessments. For data collection, 0.4 FTE were allocated in a 183 FTE department (0.2%).

Conclusions: ProPED-LUNG is feasible with high compliance rates and yields a large amount of high quality prospective disease-related, treatment-related, patient- and physician-rated data which can be used to evaluate new developments in pulmonary radiotherapy. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Originele taal-2English
Pagina's (van-tot)3-8
Aantal pagina's6
TijdschriftRadiotherapy and Oncology
Nummer van het tijdschrift1
StatusPublished - apr.-2015

Citeer dit